Lineage Cell Therapeutics (LCTX) Capital Expenditures (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Capital Expenditures of $55000.0 for Q1 2026, down 43.3% year-over-year from $97000.0 in Q1 2025, and down 88.93% quarter-over-quarter from $497000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Capital Expenditures (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $55000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 43.3% year-over-year to $55000.0; the TTM figure through Mar 2026 stood at $480000.0 (down 23.08% YoY), while the FY2025 annual figure was $522000.0, down 7.61% from the prior year.
- Capital Expenditures for Q1 2026 stood at $55000.0, down from $497000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $554000.0 in Q4 2024, with the low at -$401000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $91000.0 (2023), against an average of $108470.6.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures tumbled 374.66% in 2022, then soared 508.79% in 2024.
- Lineage Cell Therapeutics' Capital Expenditures stood at -$401000.0 in 2022, then soared by 122.69% to $91000.0 in 2023, then jumped by 508.79% to $554000.0 in 2024, then declined by 10.29% to $497000.0 in 2025, then sank by 88.93% to $55000.0 in 2026.
- Business Quant data shows LCTX's Capital Expenditures at $55000.0 in Q1 2026, $497000.0 in Q4 2025, and -$86000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 93,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 93,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 97,000.00 |
| Dec 31, 2024 | 365,000.00 |
| Sep 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | 91,000.00 |
| Sep 30, 2023 | 139,000.00 |
| Jun 30, 2023 | 256,000.00 |
| Mar 31, 2023 | 188,000.00 |
| Dec 31, 2022 | -16,000.00 |
| Sep 30, 2022 | 286,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 146,000.00 |
| Sep 30, 2021 | 54,000.00 |